Study Incidentally Implies the Negative Effectiveness of COVID Shots

The study in question is a matched cohort study that was actually examining the clinical benefit of Molnupiravir, within a 30-day window of COVID infection, for previously uninfected veterans at high risk of severe disease. So the study was not meant to directly examine the effectiveness of the primary intervention, the modRNA shot, but it incidentally does this through the results for the control group seen in figure 2

Thus absolute risk breaks down as:

429 hospitalizations and deaths from 27,053 ‘unvaccinated or primary series incomplete’ participants (0–1 shots). (1.6%).

390 hospitalizations and deaths from 15,660 ‘primary series complete, no booster’ participants (2 shots) (2.5%).

549 hospitalizations and deaths from 20,568 ‘primary series complete, booster’ participants (3–4 shots). (2.67%).

720 hospitalizations and deaths from 26,657 'primary series complete +/- booster, last dose 3 months ago.' (2.7%).

This was a matched cohort study so age and metabolic health differences were offset.

This adds to the growing body of literature showing the negative effectiveness of multiple shots including the now peer reviewed Cleveland Clinic study, Moderna's Own Clinical Trial Data for the Bivalent, A Systematic Review Published in JAMA and three smaller studies.